Publications by authors named "A Cagnacci"
The prolonged-release oral formulations: a new era in hormonal contraception technology?
Giovanni Grandi Vincenzo Bettoli Vincenzina Bruni Alessandro Gambera Rossella E Nappi Angelo Cagnacci
Eur J Contracept Reprod Health Care
January 2025
Article Synopsis
- * ET/HT can be cautiously used after vulvar cancers, melanoma, and certain endometrial cancers, while more caution is needed with adenocarcinomas and uterine sarcomas.
- * For breast cancer survivors, ET/HT is likely safe after ER/PR-negative cancers but should be applied carefully after ER/PR-positive cases.
Objectives: To compare menopausal symptoms of breast cancer survivors on adjuvant endocrine therapy with those of menopausal women.
Study Design: In a retrospective nested case-control study menopausal symptoms were compared of breast cancer survivors in pre-, peri- or post-menopause at the time of diagnosis, on tamoxifen or an aromatase inhibitor, plus a gonadotrophin-releasing hormone analogue, if pre- or peri-menopausal, and age-matched control women either in the late peri-menopause, or in surgical or in physiological post-menopause on no hormone replacement therapy. Differences between women on tamoxifen and those on aromatase inhibitors were also evaluated.
Article Synopsis
- - The study investigated whether women with endometriosis have a stiffer internal cervical os (ICO), which is linked to menstrual pain, compared to those without the condition.
- - Researchers analyzed data from 287 women, finding that those with endometriosis had significantly lower elasticity scores for the ICO and other cervical regions, indicating stiffness.
- - The results suggest a strong association between endometriosis and a stiffer ICO, even when considering other factors like myomas and hormonal therapy.
Article Synopsis
- This systematic review examines the effects of progestins as part of hormone therapy on depressive symptoms in postmenopausal women, focusing on various validated depression assessment scales.* -
- It analyzed 16 randomized clinical trials and found that adding progestins to estrogen hormone therapy did not worsen depressive symptoms and could improve them over time, although similar improvements were noted with estrogen alone.* -
- The review concluded that while progestins can be effective, the combination of estrogen with fluoxetine may lead to even greater reductions in depressive symptoms compared to hormones alone.*